Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.

Cojocaru, Elena, Thway, Khin, Fisher, Cyril, Messiou, Christina, Zaidi, Shane, Miah, Aisha B, Benson, Charlotte, Gennatas, Spyridon, Huang, Paul and Jones, Robin L (2020) Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer research, 40 (12). pp. 7003-7007. ISSN 1791-7530.

Full text not available from this repository.
Official URL: http://ar.iiarjournals.org/

Abstract

BACKGROUND/AIM

Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma.

PATIENTS AND METHODS

We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital.

RESULTS

Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months.

CONCLUSION

Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.

Item Type: Article
Subjects: QZ Pathology. Oncology
WE Musculoskeletal. Orthopaedics
WN Medical imaging. Radiology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 11 Dec 2020 15:55
Last Modified: 11 Dec 2020 15:55
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3788

Actions (login required)

View Item View Item